$AFYA

Afya (NASDAQ:AFYA) announced a merger with Yduqs, expecting BRL 2.2B in synergies. The companies will operate independently until integration. Afya reported 21% revenue and 22% EBITDA growth from 2021-2026, returning BRL 1.1B to shareholders. The merger could expand Afya's medical education pipeline and improve trading liquidity.

Afya's shares rose following an upgrade by JPMorgan. The company recently gained approval for 17 additional medical seats in Brazil. Afya's stock has seen a 17.52% increase year-to-date, with a 1.40% gain in the past five days.

Analysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.

JPMorgan upgraded Afya Ltd. (AFYA) to Overweight, citing merger synergies of R$1.8 billion and a premium higher education company. The price target was lowered to $19.00 from $21.00. Afya reported Q2 2026 revenue growth of 6% and H1 growth of 7%, with net income rising 14% in Q2 and 7% in H1. The company trades at a P/E ratio of 8 and a 23% free cash flow yield.

Afya Limited (AFYA) agreed to merge into YDUQS, with Afya shareholders receiving YDUQS shares at a fixed 6.408347 ratio and expected to own 69% of the combined company. The deal is subject to approvals, including CADE and EGMs.

Afya and Yduqs, Brazil's largest medical-education network and education group, confirmed early-stage merger talks on 24 August 2026. Yduqs shares rose 12.1% in São Paulo, while Afya's shares in New York increased 0.77%. The companies' second-quarter financials showed contrasting performances, with Afya in a stronger position. No binding agreements or details have been finalized, and both companies emphasized the preliminary nature of the discussions.

Afya (AFYA) reported Q2 2026 revenue of BRL 1.985 billion, up 7% YoY. Adjusted EBITDA rose 3% to BRL 918 million, while net income increased 7% to BRL 463 million. The company faces AI competition in clinical decision tools but is integrating AI into its iClinic platform. Management reaffirmed its full-year EBITDA guidance of BRL 1.7-1.8 billion.

Afya (NASDAQ:AFYA) reported Q2 earnings call updates. Management said medical course pricing stayed favorable and health science courses grew 13% YoY. Continuing education revenue rose 5% to BRL 144 million; medical practice solutions revenue rose 2% to BRL 85 million. Operating cash flow was BRL 806 million and free cash flow to equity BRL 423 million. Full-year adjusted EBITDA guidance was kept at BRL 1.7-1.8 billion.

Afya (AFYA) reported Q2 adjusted EPS of $0.45, slightly below the Zacks Consensus of $0.46, versus $0.40 a year earlier. Revenue was $192.36 million, marginally under the estimate. The article cites a Zacks Rank #3 (Hold) and notes upcoming consensus for the next quarter at $0.41 EPS on $196.33 million revenue.

Afya Ltd (AFYA) furnished an SEC Form 6-K — earnings release. Afya Limited Announces Second-Quarter and First-Half 2026 Financial Results R$448 Million Returned to Shareholders 106% of 1H26 FCFE Distributed Through Dividends and Share Repurchases Belo Horizonte, Brazil, August 13, 2026 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or th